Vicore Pharma AB
Ahmed Mousa is currently the Chief Executive Officer at Vicore Pharma AB, a position held since September 2023. In addition to this role, Ahmed serves as a Presidential Leadership Scholar since January 2023. Prior experience includes senior leadership positions at Pieris Pharmaceuticals as Senior Vice President, Chief Business Officer, and General Counsel from January 2016 to September 2023. Ahmed's legal career includes associate roles at Covington & Burling and Kirkland & Ellis LLP, as well as a law clerk position at the U.S. Court of Appeals for the Third Circuit. The educational background consists of a Doctor of Law degree from Georgetown University Law Center, a Master of Science in Biotechnology from The Johns Hopkins University, and a Bachelor of Arts in Molecular & Cell Biology and Government from Cornell University.
This person is not in any teams
This person is not in any offices
Vicore Pharma AB
1 followers
Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.